Integra LifeSciences Holdings Net Assets
Integra LifeSciences Holdings net assets. Based on the latest financial reports, Integra LifeSciences Holdings (IART) has net assets worth $1.04 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.58 Billion) and total liabilities ($2.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IART year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.04 Billion |
| % of Total Assets | 29.14% |
| Annual Growth Rate | 14.62% |
| 5-Year Change | -38.07% |
| 10-Year Change | 24.27% |
| Growth Volatility | 58.1 |
Net Assets of Integra LifeSciences Holdings (1995–2025)
Net assets of Integra LifeSciences Holdings from 1995 to 2025. This chart illustrates how Integra LifeSciences Holdings's net assets have evolved over time, based on quarterly financial data. See Integra LifeSciences Holdings (IART) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Integra LifeSciences Holdings (1995–2025)
The table below shows the annual net assets of Integra LifeSciences Holdings from 1995 to 2025. For live market cap and overall valuation, see IART market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.04 Billion | -32.47% |
| 2024-12-31 | $1.55 Billion | -2.68% |
| 2023-12-31 | $1.59 Billion | -12.00% |
| 2022-12-31 | $1.80 Billion | +7.10% |
| 2021-12-31 | $1.68 Billion | +11.22% |
| 2020-12-31 | $1.51 Billion | +6.93% |
| 2019-12-31 | $1.42 Billion | +2.98% |
| 2018-12-31 | $1.38 Billion | +42.97% |
| 2017-12-31 | $962.31 Million | +14.61% |
| 2016-12-31 | $839.67 Million | +11.74% |
| 2015-12-31 | $751.44 Million | +6.69% |
| 2014-12-31 | $704.32 Million | +5.09% |
| 2013-12-31 | $670.18 Million | +29.43% |
| 2012-12-31 | $517.77 Million | +5.10% |
| 2011-12-31 | $492.64 Million | -1.47% |
| 2010-12-31 | $499.96 Million | +12.38% |
| 2009-12-31 | $444.88 Million | +27.04% |
| 2008-12-31 | $350.21 Million | +34.47% |
| 2007-12-31 | $260.43 Million | -12.07% |
| 2006-12-31 | $296.16 Million | +2.19% |
| 2005-12-31 | $289.82 Million | -5.85% |
| 2004-12-31 | $307.82 Million | +14.63% |
| 2003-12-31 | $268.53 Million | +8.45% |
| 2002-12-31 | $247.60 Million | +21.34% |
| 2001-12-31 | $204.06 Million | +279.42% |
| 2000-12-31 | $53.78 Million | +41.53% |
| 1999-12-31 | $38.00 Million | +21.02% |
| 1998-12-31 | $31.40 Million | -12.29% |
| 1997-12-31 | $35.80 Million | -22.84% |
| 1996-12-31 | $46.40 Million | +166.67% |
| 1995-12-31 | $17.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integra LifeSciences Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47494100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Integra LifeSciences Holdings Net Assets Breakdown (December 2025)
Integra LifeSciences Holdings net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $423.44 Million | 40.58% |
| Common Stock | $923.00K | 0.09% |
| Other Comprehensive Income | $-30.08 Million | -2.88% |
| Other Components | $649.18 Million | 62.21% |
| Total Equity | $1.04 Billion | 100.00% |
Integra LifeSciences Holdings Competitors by Market Cap
The table below lists competitors of Integra LifeSciences Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Invisio Communications AB
ST:IVSO
|
$1.06 Billion |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
$1.06 Billion |
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
$1.06 Billion |
|
Refrigeration Electrical Engineering Corp
VN:REE
|
$1.06 Billion |
|
Zhuhai Orbita Control Eng
SHE:300053
|
$1.06 Billion |
|
AS LHV GROUP EO -10
F:ASU0
|
$1.06 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
$1.06 Billion |
|
Hyundai Development Co
KO:294870
|
$1.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integra LifeSciences Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,545,280,000 to 1,043,463,000, a change of -501,817,000 (-32.5%).
- Net loss of 516,474,000 reduced equity.
- Share repurchases of 221,000 reduced equity.
- Other comprehensive income decreased equity by 2,506,000.
- Other factors increased equity by 17,384,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-516.47 Million | -49.5% |
| Share Repurchases | $221.00K | -0.02% |
| Other Comprehensive Income | $-2.51 Million | -0.24% |
| Other Changes | $17.38 Million | +1.67% |
| Total Change | $- | -32.47% |
Book Value vs Market Value Analysis
This analysis compares Integra LifeSciences Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.44x to 1.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $0.83 | $13.63 | x |
| 1996-12-31 | $1.65 | $13.63 | x |
| 1997-12-31 | $1.21 | $13.63 | x |
| 1998-12-31 | $0.97 | $13.63 | x |
| 1999-12-31 | $1.11 | $13.63 | x |
| 2000-12-31 | $1.53 | $13.63 | x |
| 2001-12-31 | $3.67 | $13.63 | x |
| 2002-12-31 | $4.01 | $13.63 | x |
| 2003-12-31 | $4.06 | $13.63 | x |
| 2004-12-31 | $4.95 | $13.63 | x |
| 2005-12-31 | $4.19 | $13.63 | x |
| 2006-12-31 | $4.52 | $13.63 | x |
| 2007-12-31 | $4.40 | $13.63 | x |
| 2008-12-31 | $6.17 | $13.63 | x |
| 2009-12-31 | $7.59 | $13.63 | x |
| 2010-12-31 | $8.29 | $13.63 | x |
| 2011-12-31 | $8.35 | $13.63 | x |
| 2012-12-31 | $9.08 | $13.63 | x |
| 2013-12-31 | $11.63 | $13.63 | x |
| 2014-12-31 | $10.68 | $13.63 | x |
| 2015-12-31 | $10.17 | $13.63 | x |
| 2016-12-31 | $10.60 | $13.63 | x |
| 2017-12-31 | $12.16 | $13.63 | x |
| 2018-12-31 | $16.29 | $13.63 | x |
| 2019-12-31 | $16.38 | $13.63 | x |
| 2020-12-31 | $17.77 | $13.63 | x |
| 2021-12-31 | $19.71 | $13.63 | x |
| 2022-12-31 | $21.61 | $13.63 | x |
| 2023-12-31 | $19.77 | $13.63 | x |
| 2024-12-31 | $20.07 | $13.63 | x |
| 2025-12-31 | $13.60 | $13.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integra LifeSciences Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.58%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 3.45x
- Recent ROE (-49.50%) is below the historical average (-4.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -145.98% | -249.02% | 0.53x | 1.11x | $-27.14 Million |
| 1996 | -16.16% | -57.25% | 0.27x | 1.05x | $-12.14 Million |
| 1997 | -47.49% | -115.65% | 0.38x | 1.07x | $-20.58 Million |
| 1998 | -39.17% | -70.29% | 0.50x | 1.11x | $-15.44 Million |
| 1999 | -15.79% | -14.12% | 0.64x | 1.74x | $-9.80 Million |
| 2000 | -21.24% | -17.58% | 0.75x | 1.61x | $-16.80 Million |
| 2001 | 12.82% | 28.00% | 0.41x | 1.12x | $5.76 Million |
| 2002 | 14.25% | 31.32% | 0.41x | 1.11x | $10.52 Million |
| 2003 | 10.00% | 14.47% | 0.45x | 1.54x | $8.00K |
| 2004 | 5.59% | 7.48% | 0.50x | 1.48x | $-13.59 Million |
| 2005 | 12.83% | 13.38% | 0.62x | 1.55x | $8.21 Million |
| 2006 | 9.93% | 7.01% | 0.68x | 2.07x | $-209.20K |
| 2007 | 12.85% | 6.08% | 0.67x | 3.14x | $7.43 Million |
| 2008 | 9.97% | 5.34% | 0.63x | 2.95x | $-87.60K |
| 2009 | 11.45% | 7.47% | 0.73x | 2.11x | $6.47 Million |
| 2010 | 13.13% | 8.97% | 0.72x | 2.03x | $15.67 Million |
| 2011 | 5.68% | 3.59% | 0.68x | 2.32x | $-21.27 Million |
| 2012 | 7.96% | 4.96% | 0.71x | 2.25x | $-10.57 Million |
| 2013 | -2.53% | -2.03% | 0.70x | 1.78x | $-84.00 Million |
| 2014 | 4.83% | 3.66% | 0.59x | 2.24x | $-36.43 Million |
| 2015 | -0.47% | -0.40% | 0.50x | 2.36x | $-78.66 Million |
| 2016 | 8.88% | 7.52% | 0.55x | 2.15x | $-9.40 Million |
| 2017 | 6.73% | 5.45% | 0.37x | 3.34x | $-31.49 Million |
| 2018 | 4.42% | 4.13% | 0.47x | 2.26x | $-76.78 Million |
| 2019 | 3.54% | 3.31% | 0.46x | 2.33x | $-91.47 Million |
| 2020 | 8.84% | 9.76% | 0.38x | 2.39x | $-17.59 Million |
| 2021 | 10.04% | 10.96% | 0.41x | 2.24x | $594.60K |
| 2022 | 10.01% | 11.59% | 0.40x | 2.16x | $109.70K |
| 2023 | 4.27% | 4.39% | 0.41x | 2.38x | $-91.05 Million |
| 2024 | -0.45% | -0.43% | 0.40x | 2.61x | $-161.47 Million |
| 2025 | -49.50% | -31.58% | 0.45x | 3.45x | $-620.82 Million |
Industry Comparison
This section compares Integra LifeSciences Holdings's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integra LifeSciences Holdings (IART) | $1.04 Billion | -145.98% | 2.43x | $1.06 Billion |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more